NGeneBio Reports Q2 Sales of 12.45 Billion Won, Up 574% Year-on-Year

Operating Loss Improves by 55.8%
NGS Precision Diagnostics Sales Up 80.7%

Overseas Diagnostic Sales Rise 102%
Blood Cancer Panel Sales Surge 114%

NGeneBio announced on August 14 that it recorded sales of 12,452,070,000 won and an operating loss of 1,185,370,000 won in the second quarter of this year. Sales increased by 574% compared to the same period last year, while the operating loss improved by 55.8%.

NGeneBio company logo image. NGeneBio

Sales from the company's core business, the NGS (Next-Generation Sequencing) precision diagnostics division, amounted to 1,351,440,000 won, marking an 80.7% increase year-on-year. Domestic sales grew by 77.2%, while overseas sales rose by 102.1%.

Overseas, sales of blood cancer diagnostic panels surged 114% compared to the same quarter last year. The share of new markets such as Southwest Asia and the Middle East expanded from 6.1% in the second quarter last year to 34.6% this year.

NGeneBio plans to expand its 'NGS Total Solution' business—which combines NGS equipment, diagnostic panels, and analysis software—in the second half of the year, and to commercialize its AI pathology analysis software, NPAS. Internationally, it aims to expand supply in existing Southeast Asian and European markets, while also strengthening its market entry strategy for new regions such as Southwest Asia and the Middle East.

This content was produced with the assistance of AI translation services.